ClinicalTrials.Veeva

Menu

Investigating the Safety and Clinical Performance of Seven iVascular Devices for Endovascular Intervention in the Popliteal and/or Infrapopliteal Arteries (POP-BTK)

I

iVascular

Status

Enrolling

Conditions

Peripheral Arterial Disease Below The Knee

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05267548
FCRE-211206

Details and patient eligibility

About

The rationale of this study is to confirm and support the clinical safety and performance of the Oceanus 14pro, Oceanus 18 and Oceanus 35 Balloon Catheters, the Luminor 14m and Luminor 18 Drug Coated Balloons, the Angiolite BTK Sirolimus Eluting Peripheral Stent System and the Sergeant Peripheral Support Catheter in a real-word population of 143 patients who underwent an endovascular intervention the popliteal and/or infrapopliteal arteries within standard-of-care (SOC) where at least 1 of the investigational products from iVascular were used.

Enrollment

143 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Corresponding to the CE-mark indications/contra-indications and according to the IFU of the device.
  2. Patient is >18 years old.
  3. Patient understands the nature of the procedure and provides written informed consent prior to enrolment in the study.
  4. Target lesion(s) is/are located in the popliteal or infrapopliteal arteries
  5. Patient is eligible for treatment with the Oceanus 14pro Balloon Catheter and/or the Oceanus 18 Balloon Catheter and/or the Oceanus 35 Balloon Catheter and/or the Luminor 14m DCB and/or the Luminor 18 DCB and/or the Angiolite BTK Sirolimus Eluting Peripheral Stent System and/or the Sergeant Peripheral Support Catheter as described in the IFU for each device.

Exclusion criteria

  1. Anatomy or size of vessels that will not allow appropriate usage of the investigational devices, following IFU of the investigational devices.
  2. Known contraindication and/or allergy to (a component of) an investigational device.
  3. Pregnant women and women with childbearing potential not taking adequate contraceptives or currently breastfeeding.
  4. Life expectancy of less than 12 months.
  5. Any planned surgical intervention/procedure within 30 days after the study procedure.
  6. Any patient considered to be hemodynamically unstable at onset of procedure.

Trial contacts and locations

8

Loading...

Central trial contact

Mieke Ramsdonck

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems